BMJ:英国心衰患者生存期变化趋势研究——2000-2017

2019-02-20 zhangfna MedSci原创

研究认为,21世纪以来心衰患者的预后,相较于肿瘤,未得到大幅度的改善

近日研究人员就英国心衰患者短期和长期生存率的变化进行可考察。

55959名45岁新近确诊的心衰患者以及278679名性别及年龄相匹配的志愿者参与研究,考察参与者1、5、10年生存率;心衰及非心衰人群致死因素。

2000-17年间,心衰人群1、5以及10年生存率分别提升了6.6%、7.2%以及6.4%,1、5以及10年生存率分别为80.8%、48.2%和26.2%。研究期间心衰组30906名患者死亡, 13093人(42.4%)死于心衰相关疾病,其中2237人(7.2%)心衰是首要死亡因素。诊断时无需住院治疗人群的生存时间较长(2.4年),社会经济地位对生存期的影响不显著,最大仅为2.4年。

研究认为,21世纪以来心衰患者的预后,相较于肿瘤,未得到大幅度的改善。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1932646, encodeId=4a411932646ae, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat Sep 07 09:13:00 CST 2019, time=2019-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848690, encodeId=affd1848690b5, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Oct 07 05:13:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373434, encodeId=b96313e34345a, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Fri Feb 22 07:13:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378207, encodeId=e9f613e8207d0, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Feb 22 07:13:00 CST 2019, time=2019-02-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1932646, encodeId=4a411932646ae, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat Sep 07 09:13:00 CST 2019, time=2019-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848690, encodeId=affd1848690b5, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Oct 07 05:13:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373434, encodeId=b96313e34345a, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Fri Feb 22 07:13:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378207, encodeId=e9f613e8207d0, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Feb 22 07:13:00 CST 2019, time=2019-02-22, status=1, ipAttribution=)]
    2019-10-07 gaoxiaoe
  3. [GetPortalCommentsPageByObjectIdResponse(id=1932646, encodeId=4a411932646ae, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat Sep 07 09:13:00 CST 2019, time=2019-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848690, encodeId=affd1848690b5, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Oct 07 05:13:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373434, encodeId=b96313e34345a, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Fri Feb 22 07:13:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378207, encodeId=e9f613e8207d0, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Feb 22 07:13:00 CST 2019, time=2019-02-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1932646, encodeId=4a411932646ae, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat Sep 07 09:13:00 CST 2019, time=2019-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848690, encodeId=affd1848690b5, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Oct 07 05:13:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373434, encodeId=b96313e34345a, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Fri Feb 22 07:13:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378207, encodeId=e9f613e8207d0, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Feb 22 07:13:00 CST 2019, time=2019-02-22, status=1, ipAttribution=)]

相关资讯

JAMA:心衰与术后死亡风险研究

研究发现,心衰人群接受非心脏手术后90天死亡风险显著增加

真实病例分享:心衰合并糖尿病、肾功能不全,怎么办?

沙库巴曲缬沙坦钠片治心衰的同时还可带来血糖获益;并使糖尿病患者肾小球滤过率(eGFR)下降速率明显减缓,令心衰合并糖尿病患者获益更大。

BNP和NT-proBNP,你还傻傻分不清楚?

在利钠肽家族中,B型利钠肽(BNP)和N末端B型利钠肽原(NT-proBNP)是目前心衰诊疗中应用最广泛的生物标志物,有助于急慢性心衰的诊断和鉴别诊断、危险分层、疗效监测及预后评估,还有助于发现早期心衰患者、筛查心衰高危人群。深人研究这些标志物有助于阐明心衰的发病机制,更好地治疗心衰,改善心衰预后。

Radiology:评价心衰是CT好还是MRI好?

本研究旨在以延迟钆剂增强(LGE)MRI为参考标准,评价双能量CT心肌延迟强化(MDE)在检出并分类心衰患者心肌瘢痕的价值。

JACC:高密度脂蛋白颗粒与心衰预后相关

循环血中的高密度脂蛋白颗粒(HDL-P)会影响动脉粥样硬化、炎症和内皮的功能,而这些过程均与心衰的发生有关。本研究的目的旨在比较和评估决定心衰伴射血分数减少(HFrEF )的患者和心衰伴保留型射血分数(HFpEF)患者预后的HDL-P差异。本研究纳入了CATHGEN临床研究中的782名HFrEF 患者,1004名HFpEF患者和4742名无心衰患者,分析结果显示,HFrEF 患者的平均HDL-P颗

JACC Heart Fail:保留射血分数的心衰合并CKD患者 使用螺内酯请监测!

指南推荐考虑使用螺内酯来降低保留射血分数的心衰(HFpEF)患者心衰相关住院。但是,螺内酯或增加高血钾和肾功能恶化的风险,尤其是对于慢性肾病患者。2019年1月,发表在《JACC Heart Fail》的一项研究调查了保留射血分数的心衰合并慢性肾病患者使用螺内酯的有效性和安全性。